Clinical analysis of 15 patients with primary granulocytic sarcoma.
10.7534/j.issn.1009-2137.2014.02.029
- Author:
Cheng-Ying ZHU
1
;
Hua YANG
1
;
Jian-Hua NIU
2
;
Qi ZHANG
3
;
Hai-Yan ZHU
1
;
Zi-Long YAO
1
;
Li YU
1
;
Yu JING
4
Author Information
1. Department of Hematology, Chinese PLA General Hospital, Beijing 1000853, China.
2. Department of Hematology and Oncology, The Jinan Forth People's Hospital, Jinan 250031, Shandong Province, China.
3. Department of Hematology, Gaochun County People's Hospital, Nanjing 211300, Jiansu Province, China.
4. Department of Hematology, Chinese PLA General Hospital, Beijing 1000853, China. E-mail :jingyu301@126.com.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Female;
Humans;
Male;
Middle Aged;
Retrospective Studies;
Sarcoma, Myeloid;
diagnosis;
therapy;
Young Adult
- From:
Journal of Experimental Hematology
2014;22(2):425-428
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to analyze the clinical feature,diagnosis and treatment efficacy of primary granulocytic sarcoma (PGS). A total of 15 patients with PGS from January 2008 to March 2013 was evaluated retrospectively, among 15 patients 8 patients were treated with chemotherapy (chemotherapy alone,chemotherapy combined with local irradiation,chemotherapy combined with surgical resection or bone marrow transplantation), 7 patients were treated without chemotherapy, but were treated with surgical resection or surgical resection plus local irradiation.The chemotherapy method for PGS patients was similar as treatment of acute myeloid leukemia. The results indicated that the proportion of disease progression into bone marrow abnormality in patients treated with chemotherapy and in patients treated without chemotherapy was 25% and 85.7% respectively, suggesting that the chemotherapy can reduce the incidence of progression into bone marrow abnormality (P < 0.05). The average survival time of PGS patients treated with chemotherapy or without chemotherapy was 26.063 ± 14.97 and 12.214 ± 6.83 months (P < 0.05),suggesting prolonging of survival time of patients treated with chemotherapy, moreover 2 patients who were treated using chemotherapy combined with bone marrow transplantation still alive now,and their living times were 39 months and 45 months respectively. It is concluded that intensive chemotherapy similar as treatment of AML can decrease the probability of disease progressing into bone marrow abnormality, and if chemotherapy combines with bone marrow transplantation, the survival time of PGS patients can be longer. In this aspect, the efficacy of treatment and survival time at home and abroad are similar.
